Haemonetics (HAE) Reaches $78.03 After 7.00% Down Move; GUIDED THERAPEUTICS (OTCBB:GTHP) Shorts Increased By 355.51%

May 7, 2018 - By Marguerite Chambers

Haemonetics Corporation (NYSE:HAE) Logo

GUIDED THERAPEUTICS INC (OTCBB:GTHP) had an increase of 355.51% in short interest. GTHP’s SI was 103,400 shares in May as released by FINRA. Its up 355.51% from 22,700 shares previously. The stock decreased 3.53% or $0.0003 during the last trading session, reaching $0.0082. About 2.03M shares traded. Guided Therapeutics, Inc. (OTCBB:GTHP) has 0.00% since May 7, 2017 and is . It has underperformed by 11.55% the S&P500.

The stock of Haemonetics Corporation (NYSE:HAE) is a huge mover today! The stock decreased 2.38% or $1.9 during the last trading session, reaching $78.03. About 804,286 shares traded or 64.32% up from the average. Haemonetics Corporation (NYSE:HAE) has risen 82.56% since May 7, 2017 and is uptrending. It has outperformed by 71.01% the S&P500.The move comes after 8 months negative chart setup for the $4.17B company. It was reported on May, 7 by Barchart.com. We have $72.57 PT which if reached, will make NYSE:HAE worth $291.97M less.

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. The company has market cap of $1.18 million. The firm focuses on marketing LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. It currently has negative earnings. It is also developing a non-invasive esophageal cancer detection product using its biophotonic technology platform.

Since January 2, 2018, it had 0 insider purchases, and 3 sales for $484,765 activity. $28,097 worth of stock was sold by Basil Michelle L on Tuesday, March 6. Shares for $8,234 were sold by Scanlan Jacqueline on Tuesday, March 6. KROLL MARK W also sold $448,434 worth of Haemonetics Corporation (NYSE:HAE) on Tuesday, January 2.

Among 10 analysts covering Haemonetics Corporation (NYSE:HAE), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Haemonetics Corporation had 28 analyst reports since July 29, 2015 according to SRatingsIntel. As per Thursday, November 9, the company rating was maintained by Morgan Stanley. Barrington Research upgraded Haemonetics Corporation (NYSE:HAE) rating on Tuesday, July 28. Barrington Research has “Outperform” rating and $43 target. The firm earned “Outperform” rating on Tuesday, October 6 by Barrington Research. As per Tuesday, September 20, the company rating was downgraded by CJS Securities. The firm earned “Equal-Weight” rating on Friday, October 6 by Morgan Stanley. On Tuesday, January 2 the stock rating was upgraded by Morgan Stanley to “Overweight”. As per Wednesday, March 28, the company rating was maintained by Morgan Stanley. Raymond James downgraded the stock to “Underperform” rating in Monday, November 23 report. The firm has “Outperform” rating given on Tuesday, November 8 by Barrington Research. The stock of Haemonetics Corporation (NYSE:HAE) has “Hold” rating given on Wednesday, November 8 by Craig Hallum.

Investors sentiment decreased to 1.11 in Q4 2017. Its down 0.17, from 1.28 in 2017Q3. It dived, as 20 investors sold Haemonetics Corporation shares while 77 reduced holdings. 48 funds opened positions while 60 raised stakes. 50.89 million shares or 3.15% less from 52.55 million shares in 2017Q3 were reported. Amalgamated National Bank & Trust owns 7,752 shares for 0.01% of their portfolio. Retail Bank Of Ny Mellon Corp owns 664,964 shares. Gotham Asset Mngmt Ltd Liability Corp has invested 0.02% in Haemonetics Corporation (NYSE:HAE). The California-based California Pub Employees Retirement has invested 0.01% in Haemonetics Corporation (NYSE:HAE). Orrstown Financial Svcs accumulated 32 shares. 21,684 are owned by Us Bankshares De. North Star Asset Mngmt accumulated 3,800 shares. Comerica Natl Bank holds 0.03% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 57,855 shares. Chilton Inv Limited Liability Company holds 0.49% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 217,825 shares. Numeric Limited Liability Company invested in 123,100 shares or 0.05% of the stock. 10,442 are owned by Sei Invests. Shelton Capital Mngmt accumulated 4,699 shares or 0.02% of the stock. Boston Advsr Limited has 47,725 shares for 0.06% of their portfolio. Brinker Capital stated it has 0.01% in Haemonetics Corporation (NYSE:HAE). 33,273 are owned by Voya Invest Management Lc.

Analysts await Haemonetics Corporation (NYSE:HAE) to report earnings on May, 8 before the open. They expect $0.43 EPS, up 10.26% or $0.04 from last year’s $0.39 per share. HAE’s profit will be $22.99M for 45.37 P/E if the $0.43 EPS becomes a reality. After $0.62 actual EPS reported by Haemonetics Corporation for the previous quarter, Wall Street now forecasts -30.65% negative EPS growth.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $4.17 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It currently has negative earnings. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Haemonetics Corporation (NYSE:HAE) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: